Skip to main content
Top
Published in: Rheumatology and Therapy 4/2023

Open Access 19-06-2023 | Vaccination | Original Research

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases

Authors: Yan Geng, Yong Fan, Xuerong Deng, Yu Wang, Juan Zhao, Lanlan Ji, Zhibo Song, Guangtao Li, Xiaohui Zhang, Xiaoying Sun, Hong Huang, Wenhui Xie, Zhuoli Zhang

Published in: Rheumatology and Therapy | Issue 4/2023

Login to get access

Abstract

Introduction

The impact of coronavirus disease 2019 (COVID-19) on vulnerable populations with autoimmune inflammatory rheumatic diseases (AIIRDs) has been variable with variants and of great concern. Here we report the clinical features, outcomes, and risk factors for infection and hospitalization in patients with AIIRDs in the first wave of infection in China in December 2022.

Methods

A real-world survey was conducted in Chinese patients with AIIRDs from 8 December 2022 to 13 January 2023. The survey was distributed via internet nationwide, clinic consultation, and to inpatients at a tertiary hospital in Beijing. Clinical features, outcomes, and vaccination status were collected.

Results

A total of 2005 patients with AIIRDs completed the survey. There were 1690 (84.3%) patients infected and only 48.2% of patients received COVID-19 vaccination. Most of the fully vaccinated patients received inactivated COVID-19 vaccines, including Sinovac (55.6%) and Sinopharm (27.2%), followed by recombinant subunit vaccine from Zhifei Longcom (2.0%). The independent protecting factors for infection were a time interval of less than 3 months from last vaccination (OR 0.53, p = 0.037) and rheumatoid arthritis (RA) as the underlying AIIRD (OR 0.62, p = 0.041). A total of 57 out of 1690 patients (3.4%) were hospitalized for COVID, with 46 (2.7%) experiencing severe/critical course and 6 deaths (0.4%). In multivariable logistic regression analysis, independent risk factors for hospitalization were age over 60 years (OR 11.52, p < 0.001), with comorbidity (OR 1.83, p = 0.045) and systemic lupus erythematosus (SLE) as the AIIRDs (OR 2.59, p = 0.036). Receiving booster vaccine was an independent protective factor for hospitalization (OR 0.53, 95% CI 0.30–0.98; p = 0.018).

Conclusion

Hesitation for vaccination is common among Chinese patients with AIIRDs. The time from last vaccination of less than 3 months and having RA decreased the risk of COVID infection. Older age and having comorbidity or SLE increased the risk of hospitalization, while booster vaccination reduced the risk.
Literature
1.
go back to reference Fernandez-Gutierrez B. COVID-19 with pulmonary involvement. An autoimmune disease of known cause. Reumatol Clin (Engl Ed). 2020;16(4):253–4.CrossRefPubMed Fernandez-Gutierrez B. COVID-19 with pulmonary involvement. An autoimmune disease of known cause. Reumatol Clin (Engl Ed). 2020;16(4):253–4.CrossRefPubMed
2.
go back to reference Gates B. Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–9.CrossRefPubMed Gates B. Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–9.CrossRefPubMed
3.
go back to reference Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(6):839–40.CrossRefPubMed Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(6):839–40.CrossRefPubMed
5.
go back to reference Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev. 2021;20(4):102778.CrossRefPubMedPubMedCentral Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev. 2021;20(4):102778.CrossRefPubMedPubMedCentral
6.
go back to reference Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet (London, England). 2020;395(10225):683–4.CrossRefPubMed Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet (London, England). 2020;395(10225):683–4.CrossRefPubMed
7.
go back to reference Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.CrossRefPubMedPubMedCentral Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.CrossRefPubMedPubMedCentral
8.
go back to reference Bijlsma JW, Force EC-T. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis. 2022;81(6):786–8.CrossRefPubMed Bijlsma JW, Force EC-T. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions. Ann Rheum Dis. 2022;81(6):786–8.CrossRefPubMed
9.
go back to reference Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 2023;75(1):e1–16.CrossRefPubMed Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 2023;75(1):e1–16.CrossRefPubMed
10.
go back to reference Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–8.CrossRefPubMed Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–8.CrossRefPubMed
11.
go back to reference Kim WJ, Choi SH, Park JY, Song JS, Chung JW, Choi ST. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Ann Rheum Dis. 2022;81(11):1585–93.CrossRefPubMed Kim WJ, Choi SH, Park JY, Song JS, Chung JW, Choi ST. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Ann Rheum Dis. 2022;81(11):1585–93.CrossRefPubMed
12.
go back to reference Papagoras C, Fragoulis GE, Zioga N, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013–6.CrossRefPubMed Papagoras C, Fragoulis GE, Zioga N, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013–6.CrossRefPubMed
13.
go back to reference Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19-COVID-NET, 10 states, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878–84.CrossRefPubMedPubMedCentral Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19-COVID-NET, 10 states, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878–84.CrossRefPubMedPubMedCentral
14.
go back to reference Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 infection and hospitalization among adults aged >/=18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance-Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5):177–81.CrossRefPubMedPubMedCentral Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 infection and hospitalization among adults aged >/=18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance-Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5):177–81.CrossRefPubMedPubMedCentral
15.
go back to reference Liew J, Gianfrancesco M, Harrison C, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open. 2022;8(1):e002187. Liew J, Gianfrancesco M, Harrison C, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open. 2022;8(1):e002187.
16.
go back to reference Widdifield J, Kwong JC, Chen S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022;4(6):e430–40.CrossRefPubMedPubMedCentral Widdifield J, Kwong JC, Chen S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022;4(6):e430–40.CrossRefPubMedPubMedCentral
17.
go back to reference Bakasis AD, Mavragani CP, Voulgari PV, et al. COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun. 2022;131: 102846.CrossRefPubMedPubMedCentral Bakasis AD, Mavragani CP, Voulgari PV, et al. COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun. 2022;131: 102846.CrossRefPubMedPubMedCentral
18.
go back to reference Fan Y, Geng Y, Wang Y, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis. 2022;81(3):443–5.CrossRefPubMed Fan Y, Geng Y, Wang Y, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis. 2022;81(3):443–5.CrossRefPubMed
20.
go back to reference Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724–36.CrossRefPubMedPubMedCentral Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724–36.CrossRefPubMedPubMedCentral
21.
go back to reference Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19(5):102523.CrossRefPubMedPubMedCentral Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19(5):102523.CrossRefPubMedPubMedCentral
22.
go back to reference Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.CrossRefPubMedPubMedCentral Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.CrossRefPubMedPubMedCentral
23.
go back to reference Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851–61.CrossRefPubMedPubMedCentral Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851–61.CrossRefPubMedPubMedCentral
24.
go back to reference Freites Nunez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393–9.CrossRefPubMed Freites Nunez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393–9.CrossRefPubMed
25.
go back to reference Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544–9.CrossRefPubMed Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544–9.CrossRefPubMed
26.
go back to reference Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol. 2022;41(9):2893–910.CrossRefPubMedPubMedCentral Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol. 2022;41(9):2893–910.CrossRefPubMedPubMedCentral
Metadata
Title
The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases
Authors
Yan Geng
Yong Fan
Xuerong Deng
Yu Wang
Juan Zhao
Lanlan Ji
Zhibo Song
Guangtao Li
Xiaohui Zhang
Xiaoying Sun
Hong Huang
Wenhui Xie
Zhuoli Zhang
Publication date
19-06-2023
Publisher
Springer Healthcare
Published in
Rheumatology and Therapy / Issue 4/2023
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI
https://doi.org/10.1007/s40744-023-00569-7

Other articles of this Issue 4/2023

Rheumatology and Therapy 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.